NOVORON BIOSCIENCE INC

SAN DIEGO, CA · Biotech · Private

Therapeutic approaches for central nervous system neurological damage and disease

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · novoron.com

Sector: Biotech
Headquarters: SAN DIEGO, CA
Latest Form D: $12.1M, Dec 2022
Total capital: $21.4M

Federal grants: $6.2M; 15 awards · 2015–2026; Rank in peer group#14 of 48
Private capital raised: $15.2M; 2 Form D · last Dec 2022; 46 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 4 pending

Capital timeline

Latest events

Jun 2026Federal grantHealth and Human S · Phase II · Human iPSC neural spheroids to screen for compounds that block tau propagation$1.2M
Sep 2025Federal grantHealth and Human S · Phase II · Human iPSC neural spheroids to screen for compounds that block tau propagation$1.3M
Dec 2022Private capital raisedForm D · SEC · 2nd filing$12.1M
Aug 2022Federal grantHealth and Human S · Phase I · A novel approach to restricting the spread of neurofibrillary tau$110K
Aug 2022Federal grantHealth and Human S · Phase I · A novel approach to restricting the spread of neurofibrillary tau$348K
Apr 2022Federal grantHealth and Human S · Phase I · A novel approach to restricting the spread of neurofibrillary tau$37K
Aug 2021Federal grantHealth and Human S · Phase I · A novel approach to restricting the spread of neurofibrillary tau$350K
Jul 2021Private capital raisedForm D · SEC · 1st filing$3M

Show 9 earlier federal awards

Jun 2020Federal grantHealth and Human S · Phase I · NOVO-118 as a therapeutic to promote remyelination in in vivo models of MS$354K
Sep 2019Federal grantHealth and Human S · Phase I · NOVO-118 as a therapeutic to promote remyelination in in vivo models of MS$353K
Mar 2019Federal grantHealth and Human S · Phase I · Assessment of NOVO-118 as a regenerative therapeutic in acute spinal cord injury$348K
Mar 2018Federal grantHealth and Human S · Phase I · Assessment of NOVO-118 as a regenerative therapeutic in acute spinal cord injury$348K
Sep 2016Federal grantHealth and Human S · Phase I · RAP as a novel therapeutic to promote remyelination after MS demyelinating event$321K
Sep 2015Federal grantHealth and Human S · Phase I · RAP as a novel therapeutic to promote remyelination after MS demyelinating event$674K
Sep 2015Federal grantHealth and Human S · Phase I · RAP as a novel therapeutic to promote remyelination after MS demyelinating event$353K
Sep 2015Federal grantHealth and Human S · Phase I · RAP as a therapeutic for regeneration of the optic nerve after insult$40K
Apr 2015Federal grantHealth and Human S · Phase I · RAP as a therapeutic compound for neuronal regeneration after spinal cord injury$80K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

75months

from NOVORON BIOSCIENCE INC’s first federal award to its first private round.

First federal award · Apr 2015: Health and Human S · $80K
First Form D · Jul 2021: $3M · 1st Form D
Awards before first raise: 9 awards

An association in public records, not a cause or a prediction.

Standing among 48 peers

Line = median

Biotech · Platform

Federal grants#14 · top 29%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Travis StilesResearcherExecutive Officer, DirectorLinked by $674K in grants as PI
Michael GoguenDirectorNamed in SEC Form D filings
Shawn GahrExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 4

Jan 15, 2026PendingMethods And Compositions For Promoting Opc Differentiation And Remyelination Using Receptor Associated Protein (rap)USPTOApplication 19098937
Dec 24, 2020PendingMethods And Compositions For Promoting Opc Differentiation And Remyelination Using Receptor Associated Protein (rap)USPTOApplication 16867058
Mar 21, 2019PendingMethods And Compositions For Promoting Opc Differentiation And Remyelination Using Receptor Associated Protein (rap)USPTOApplication 16138743

Show all 4 patent records

Methods And Compositions For Promoting Opc Differentiation And Remyelination Using Receptor Associated Protein (rap)Jan 15, 2026 · Application 19098937Pending
Methods And Compositions For Promoting Opc Differentiation And Remyelination Using Receptor Associated Protein (rap)Dec 24, 2020 · Application 16867058Pending
Methods And Compositions For Promoting Opc Differentiation And Remyelination Using Receptor Associated Protein (rap)Mar 21, 2019 · Application 16138743Pending
Methods And Compositions For Promoting Opc Differentiation And Remyelination Using Receptor Associated Protein (rap)Application PCTUS2017023481Pending

ADVANCED PROCESS COMBINATORICS, INC.Similar federal contract value in Biotech · null in contracts
Atara BiotherapeuticsSimilar federal contract value in Biotech · null in contracts
IMMUNEXT, INC.Similar federal contract value in Biotech · null in contracts
ADAPTIN BIO, INC.Similar federal contract value in Biotech · null in contracts
Tolera Therapeutics IncSimilar federal contract value in Biotech · null in contracts
IllExcor Therapeutics LLCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.